A clinical study to evaluate efficacy and safety of AHPL/AYTAB/0313 in subjects suffering from osteoarthritis of knee(s) - NI

Ari Healthcare Pvt Ltd0 个研究点目标入组 48 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Subject willing to participate, who have read, understood and signed informed consent form
•2.Subject with history of knee pain due to osteoarthritis requiring use of NSAIDs acetaminophen, or another analgesic agent on a regular basis (greater than or equal to 3 days per week) for at least 6 months before the screening visit.
•3.OA confirmed by radiographs and diagnosed according to ACR diagnostic criteria (clinical and radiological) for the OA of the knee.
•4.Subjects are willing to make all required study visits
•5.Subjects are willing to follow study instructions given by the investigator

•1.Subjects refused to give their informed consent
•2.Subjects with rheumatoid arthritis, gout, pseudo gout, inflammatory arthritis, Pagets disease of bone, chronic pain syndrome, fibromyalgia, or another major joint disease
•3.Subjects with history of surgery, including arthroscopy, or major trauma to the study joint in the previous six months before the screening visit
•4.Subjects requiring knee arthroplasty within 6 months of screening or anticipating any need for a surgical procedure on the index joint during the study
•5.Subjects with signs of clinically important active inflammation of the study knee joint including redness, warmth and or a large, bulging effusion with the loss of normal contour at the screening and or baseline visits
•6.Subjects using systemic corticosteroids within 2 months of screening, or intraarticular visco-supplementation within the past 3 months
•7.Subjects with any other investigational drug within 1 month prior to randomization;
•8.Subjects having diabetes mellitus, tuberculosis, HIV, ischemic heart disease
•9.Subjects with known major medical or surgical disease
•10.Pregnant and lactating women
•11.Subjects with known hypersensitivity to ingredients used in study drug.
•12.Subjects with significant abnormal laboratory parameters
•13.ECG demonstrating any signs of uncontrolled arrhythmia and or acute ischemia

发起方

Ari Healthcare Pvt Ltd